Company / Shareholders' Equity
ANI Pharmaceuticals, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$540.7M
FY2025
5-year range
$313.7M / $540.7M
FY2021-FY2025
Trend
+33.9%
vs FY2024
Sector context
#89 of 213
Health Care
What the data says
At $541M, ANI Pharmaceuticals, Inc.'s shareholders' equity ranks #89 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $170M in FY2016 to $541M in FY2025.
Based on SEC 10-K filings.
$541M in FY2025 with a 5-year CAGR of +22.5%.
Improved from $433M to $541M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +19.9%
- 5-Year CAGR
- +22.5%
- 10-Year CAGR
- -
Sector benchmark
#89 of 213 in Health CareTop 42% of 213This company $540.7M Sector average $2.5B
▼
-78.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 33.9% year-over-year.
- Ranks #89 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $540.7M | +33.9% |
| FY2024 | $403.7M | -6.7% |
| FY2023 | $432.7M | +38.0% |
| FY2022 | $313.7M | -6.0% |
| FY2021 | $333.9M | +70.6% |
| FY2020 | $195.7M | -8.0% |
| FY2019 | $212.8M | +7.9% |
| FY2018 | $197.3M | +12.9% |
| FY2017 | $174.8M | +3.0% |
| FY2016 | $169.6M | +314.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026